Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 1.00 |
| ▸ | PRKCB | P05771 | 3/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 3/20 | 1.00 |
| ▸ | PIM1 | P11309 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | HIPK1 | Q86Z02 | 2/20 | 1.00 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 1.00 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisindolylmaleimide Ix SCHEMBL1567017 | 1.00 | PRKCA (1.00) | PRKCAPRKCBPRKCEPIM1MEN1 | |
| Bisindolylmaleimide Ix SCHEMBL29381390 | 0.95 | MEN1 (1.00) | PRKCAPRKCBPRKCEPIM1MEN1 | |
| Bisindolylmaleimide Ix SCHEMBL2491726 | 0.95 | MEN1 (1.00) | PRKCAPRKCBPRKCEPIM1MEN1 | |
| SCHEMBL8166772 | 0.93 | MEN1 (0.95) | PRKCAPRKCBPRKCEPIM1MEN1 | |
| SCHEMBL8161675 | 0.92 | MEN1 (0.93) | PRKCAPRKCBPRKCEPIM1MEN1 | |
| SCHEMBL15600252 | 0.91 | PIM1 (0.83) | PRKCAPRKCBPRKCEPIM1MEN1 | |
| SCHEMBL18134615 | 0.90 | PIM1 (0.81) | PRKCAPRKCBPRKCEPIM1MEN1 | |
| SCHEMBL8154377 | 0.89 | MEN1 (0.89) | PRKCAPRKCBPRKCEPIM1MEN1 | |
| SCHEMBL8160916 | 0.88 | PIM1 (0.78) | PRKCAPRKCBPRKCEPIM1MEN1 | |
| SCHEMBL9088345 | 0.86 | PRKCB (0.76) | PRKCAPRKCBPRKCEPIM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4627062-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | claimed |
| WO-2025120106-A1 | METHODS FOR ISOLATING EMBRYONIC STEM CELLS FROM AN AVIAN EMBRYO CELLS | SUPRÊME (FR) | 2025-06-12 | — | — | WO | claimed |
| EP-4567102-A1 | METHODS FOR ISOLATING EMBRYONIC STEM CELLS FROM AVIAN EMBRYONIC CELLS | Suprême (FR) | 2025-06-11 | — | — | EP | claimed |
| US-20250163388-A1 | METHODS FOR DERIVATION AND PROPAGATION OF AVIAN PLURIPOTENT STEM CELLS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-05-22 | — | — | US | claimed |
| US-12215355-B2 | Stem cell derived islet differentiation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-02-04 | — | — | US | claimed |
| US-12188046-B2 | Culture medium, coating matrix and method for expanding midbrain dopaminergic progenitor cells | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-01-07 | — | — | US | claimed |
| EP-4479521-A2 | METHODS FOR DERIVATION AND PROPAGATION OF AVIAN PLURIPOTENT STEM CELLS AND APPLICATIONS THEREOF | University of Southern California (US) | 2024-12-25 | — | — | EP | claimed |
| EP-4461806-A2 | SC-B CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | President and Fellows of Harvard College (US) | 2024-11-13 | — | — | EP | claimed |
| US-20240358767-A1 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-31 | — | — | US | claimed |
| US-20240352413-A1 | ISOLATED HUMAN LUNG PROGENITOR CELLS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2024-10-24 | — | — | US | claimed |
| US-20230201173-A1 | SMAD4 Complex Inducers and Uses in Cancer Therapy | UNIV EMORY (US) | 2023-06-29 | — | — | US | claimed |
| WO-2023081884-A2 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-05-11 | — | — | WO | claimed |
| US-20230079757-A1 | METHODS AND MATERIALS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2023-03-16 | — | — | US | claimed |
| US-20230031009-A1 | TREATMENT FOR CHEMOBRAIN | UNIV YALE (US) | 2023-02-02 | — | — | US | claimed |
| EP-4107278-A1 | METHODS AND MATERIALS FOR TREATING CANCER | Mayo Foundation for Medical Education and Research (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-12-01 | — | — | US | claimed |
| WO-2022192300-A1 | STEM CELL DIFFERENTIATION AND POLYMERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-09-15 | — | — | WO | claimed |
| WO-2022147056-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-07-07 | — | — | WO | claimed |
| WO-2022120187-A2 | METHOD OF DETERMINING RESISTANCE TO CHECKPOINT INHIBITOR THERAPIES | SHATTUCK LABS, INC. (US) | 2022-06-09 | — | — | WO | claimed |
| US-20220162562-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | HARVARD COLLEGE (US) | 2022-05-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | PRKCA 430/4885PRKCB 296/4885PRKCE 432/4885 |
| US-20240358767-A1 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | EBP, AKT3, PRKCD | PRKCA 11/4885PRKCB 6/4885PRKCE 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.